Neurizon Therapeutics (ASX: NUZ) has reported positive results from an independent study into the effects of neuroprotective ...

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective candidate, NUZ-001, using Tessara Therapeutics' 3D human brain model. The ...

Special Report: Ahead of near-term readouts from a trial investigating NUZ-001’s effect in a mouse model of Parkinson’s, ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold ...

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this video are opinions only and not ...

Watch the video to hear more. This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

Neurizon Therapeutics (ASX:NUZ) has confirmed its lead drug candidate has neuroprotective potential in an independent study. The study’s authors noted that NUZ-001’s cell survival effect was ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold on its IND application for NUZ-001 Neurizon Therapeutics (ASX ...